Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
24.99
+0.18 (0.73%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
$252,026
Profits / Employee
-$105,501
Market Cap
2.81B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 540 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 289 |
| Precigen | 160 |
| Celcuity | 155 |
ZLAB News
- 11 days ago - Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - Business Wire
- 6 weeks ago - Zai Lab price target raised to $36 from $27 at JPMorgan - TheFly
- 6 weeks ago - Z.ai shares surge 8% after releasing new AI model running only on Chinese chips - CNBC
- 7 weeks ago - Zai Lab (ZLAB) CFO Yajing Chen Sells 260 Shares, Insider Selling Trend Persists - GuruFocus
- 7 weeks ago - Zai Lab and Argenx announce results from Alkivia Phase 3 study - TheFly
- 7 weeks ago - Zai Lab and Argenx announce results from Alkivia Phase 3 study - TheFly
- 7 weeks ago - Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis - Business Wire
- 1 month ago - Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript - The Motley Fool